IOVANCE Biotherapeutics is focused on improving patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
CLINICAL TRIALS– Now Recruiting
IOVANCE is recruiting patients in four Phase 2 clinical trials to assess the efficacy and safety of autologous cell therapies for treatment of patients with cancer.
C-145-04 is a multicenter clinical trial in patients with metastatic cervical cancer at various sites in the U.S. and Europe.
IOV-LUN-202 is a Phase 2 multicenter clinical trial in patients with metastatic non-small cell lung cancer (NSCLC).
IOV-COM-202 is a multicenter clinical trial now recruiting patients with non-small cell lung cancer (NSCLC), metastatic melanoma, and head and neck squamous cell carcinoma (HNSCC) at various sites in the U.S., Canada and Europe.
IOV-CLL-01 is a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).Learn